Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer

被引：0
|
作者：
Hiroki Goya
Hiroshi Kuraishi
Shigeru Koyama
Takashi Ichiyama
Fumiaki Yoshiike
Kazuya Hirai
Toshihiko Agatsuma
Kazunari Tateishi
Shintaro Kanda
Hiroshi Yamamoto
Keishi Kubo
Tomonobu Koizumi
机构：
[1] Nagano Red Cross Hospital,Respiratory Division
[2] Nagano Municipal Hospital,Respiratory Division
[3] Shinshu University School of Medicine,First Department of Internal Medicine
[4] Shinshu University Hospital School of Medicine,Division of Clinical Oncology, Comprehensive Cancer Center
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 70卷
关键词：
Chemo-refractory; Salvage chemotherapy; Second line; CTP-11;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：691 / 697
页数：6
相关论文
共 50 条
  • [41] Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine
    Takashi Sasaki
    Hiroyuki Isayama
    Yousuke Nakai
    Suguru Mizuno
    Keisuke Yamamoto
    Hiroshi Yagioka
    Yoko Yashima
    Kazumichi Kawakubo
    Hirofumi Kogure
    Osamu Togawa
    Saburo Matsubara
    Yukiko Ito
    Naoki Sasahira
    Kenji Hirano
    Takeshi Tsujino
    Nobuo Toda
    Minoru Tada
    Masao Omata
    Kazuhiko Koike
    Investigational New Drugs, 2012, 30 : 708 - 713
  • [42] Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer
    Asao, Tetsuhiko
    Nokihara, Hiroshi
    Yoh, Kiyotaka
    Niho, Seiji
    Goto, Koichi
    Ohmatsu, Hironobu
    Kubota, Kaoru
    Yamamoto, Noboru
    Sekine, Ikuo
    Kunitoh, Hideo
    Fujiwara, Yutaka
    Ohe, Yuichiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (10) : 941 - 946
  • [43] Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine
    Sasaki, Takashi
    Isayama, Hiroyuki
    Nakai, Yousuke
    Mizuno, Suguru
    Yamamoto, Keisuke
    Yagioka, Hiroshi
    Yashima, Yoko
    Kawakubo, Kazumichi
    Kogure, Hirofumi
    Togawa, Osamu
    Matsubara, Saburo
    Ito, Yukiko
    Sasahira, Naoki
    Hirano, Kenji
    Tsujino, Takeshi
    Toda, Nobuo
    Tada, Minoru
    Omata, Masao
    Koike, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 708 - 713
  • [44] Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC
    Sugawara, Shunichi
    Nakagawa, Kazuhiko
    Yamamoto, Nobuyuki
    Nokihara, Hiroshi
    Ohe, Yuichiro
    Nishio, Makoto
    Takahashi, Toshiaki
    Goto, Koichi
    Maemondo, Makoto
    Ichinose, Yukito
    Seto, Takashi
    Sakai, Hiroshi
    Gemma, Akihiko
    Imamura, Fumio
    Shingyoji, Masato
    Saka, Hideo
    Inoue, Akira
    Takeda, Koji
    Okamoto, Isamu
    Kiura, Katsuyuki
    Morita, Satoshi
    Tamura, Tomohide
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (05) : 485 - 493
  • [45] Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC
    Shunichi Sugawara
    Kazuhiko Nakagawa
    Nobuyuki Yamamoto
    Hiroshi Nokihara
    Yuichiro Ohe
    Makoto Nishio
    Toshiaki Takahashi
    Koichi Goto
    Makoto Maemondo
    Yukito Ichinose
    Takashi Seto
    Hiroshi Sakai
    Akihiko Gemma
    Fumio Imamura
    Masato Shingyoji
    Hideo Saka
    Akira Inoue
    Koji Takeda
    Isamu Okamoto
    Katsuyuki Kiura
    Satoshi Morita
    Tomohide Tamura
    International Journal of Clinical Oncology, 2019, 24 : 485 - 493
  • [46] A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer
    Sculier, JP
    Lafitte, JJ
    Berghmans, T
    Thiriaux, J
    Lecomte, J
    Efremidis, A
    Ninane, V
    Paesmans, M
    Mommen, P
    Klastersky, J
    LUNG CANCER, 2000, 29 (01) : 67 - 73
  • [47] Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel
    Chen, YM
    Shih, JF
    Lee, CS
    Chen, MC
    Lin, WC
    Tsai, CM
    Perng, RP
    LUNG CANCER, 2003, 39 (02) : 209 - 214
  • [48] Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study
    Dai, Xichao
    Tao, Leilei
    Wang, Jinqiu
    Wu, Wenjuan
    Bian, Weigang
    Dai, Xichun
    Chen, Surong
    CANCER MEDICINE, 2023, 12 (15): : 16108 - 16118
  • [49] Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study
    Bersanelli, Melissa
    Buti, Sebastiano
    Giannarelli, Diana
    Leonetti, Alessandro
    Cortellini, Alessio
    Lo Russo, Giuseppe
    Signorelli, Diego
    Toschi, Luca
    Milella, Michele
    Pilotto, Sara
    Bria, Emilio
    Proto, Claudia
    Marinello, Arianna
    Randon, Giovanni
    Rossi, Sabrina
    Vita, Emanuele
    Sartori, Giulia
    D'Argento, Ettore
    Qako, Eva
    Giaiacopi, Elisa
    Ghilardi, Laura
    Bettini, Anna Cecilia
    Rapacchi, Elena
    Mazzoni, Francesca
    Lavacchi, Daniele
    Scotti, Vieri
    Ciccone, Lucia Pia
    De Tursi, Michele
    Di Marino, Pietro
    Santini, Daniele
    Russano, Marco
    Bordi, Paola
    Di Maio, Massimo
    Audisio, Marco
    Filetti, Marco
    Giusti, Raffaele
    Berardi, Rossana
    Fiordoliva, Ilaria
    Cerea, Giulio
    Pizzutilo, Elio Gregory
    Bearz, Alessandra
    De Carlo, Elisa
    Cecere, Fabiana
    Renna, Davide
    Camisa, Roberta
    Caruso, Giuseppe
    Ficorella, Corrado
    Banna, Giuseppe Luigi
    Cortinovis, Diego
    Brighenti, Matteo
    LUNG CANCER, 2020, 150 : 123 - 131
  • [50] Response to Salvage Chemotherapy Following Exposure to PD-1 Inhibitors in Patients with Non-Small Cell Lung Cancer
    Leger, Paul
    Castellanos, Emily
    Pillai, Rathi
    Horn, Leora
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S918 - S919
12345